For this retrospective analysis, we included all kidney transplant recipients with dnDSA from 01/03/2000 until 31/05/2021 (end of follow-up) at Charité-Universitätsmedizin Berlin (Germany). All patients with dnDSA against the last graft with complete HLA typing were included, excluding those patients with preformed DSA before transplantation. The primary outcome variable in our study was time to death-censored graft failure, defined as graft loss (i.e., the need for permanent dialysis, allograft nephrectomy, or re-transplantation). Patients who developed dnDSA after graft loss were excluded.
All data including estimated glomerular filtration rate (GFR, ml/min), proteinuria (mg/g creatinine), delayed graft function (DGF), defined as the need for dialysis within 7 days of transplant, and biopsy data were collected from the prospectively maintained database (TBase) (49 (link)). All rejections were categorized according to Banff 2017 classification (5 (link), 50 (link), 51 (link)). Calculated panel-reactive antibody (cPRA) was obtained through the Virtual PRA Calculator of the Eurotransplant Reference Laboratory.1 No institutional review board approval was required for this retrospective analysis.
All data including estimated glomerular filtration rate (GFR, ml/min), proteinuria (mg/g creatinine), delayed graft function (DGF), defined as the need for dialysis within 7 days of transplant, and biopsy data were collected from the prospectively maintained database (TBase) (49 (link)). All rejections were categorized according to Banff 2017 classification (5 (link), 50 (link), 51 (link)). Calculated panel-reactive antibody (cPRA) was obtained through the Virtual PRA Calculator of the Eurotransplant Reference Laboratory.
Free full text: Click here
